Organogenesis Begins Rolling Submission for ReNu Allograft to Treat Knee Arthritis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Should l Buy ORGO?
Source: SeekingAlpha
BLA Submission for ReNu: Organogenesis has initiated a rolling Biologics License Application (BLA) submission for ReNu, a cryopreserved amniotic suspension allograft aimed at treating symptomatic knee arthritis.
Composition and Support: ReNu consists of amniotic fluid cells, micronized amniotic membrane, and various cellular and growth factor components, with its application backed by results from three randomized, controlled trials.
Completion Timeline: The company expects to finalize the rolling BLA submission by the first half of 2026.
Financial Outlook: Organogenesis projects a revenue guidance of $500M–$525M for 2025, bolstered by favorable CMS policy changes, and reported a Q3 2025 GAAP EPS of $0.11, exceeding expectations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORGO
Wall Street analysts forecast ORGO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.760
Low
9.00
Averages
9.00
High
9.00
Current: 2.760
Low
9.00
Averages
9.00
High
9.00
About ORGO
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Organogenesis Reports Record Q4 2025 Earnings Amid Market Uncertainty
- Record Sales: Organogenesis achieved net product revenue of $225.1 million in Q4 2025, representing a 78% year-over-year increase and exceeding expectations by $50 million, primarily driven by an 83% growth in Advanced Wound Care product sales, reflecting strong market demand and effective customer relationships.
- Gross Margin Improvement: The gross profit for Q4 was $175.2 million, or 78% of net product revenue, up from 75% last year, indicating success in cost control and pricing strategies, despite operating expenses rising 39% year-over-year.
- 2026 Outlook: The CFO projected a 25% to 38% decline in total net revenue for 2026, primarily due to clinical confusion stemming from CMS policy changes, with first-quarter revenue expected to drop approximately 50%, although the company remains optimistic about market share growth in the second half of the year.
- Strategic Investments: The CEO highlighted investments in a new manufacturing and R&D center in Rhode Island, along with the launch of Dermagraft and expansion plans for FortiShield and TransCyte, demonstrating the company's commitment to long-term growth and entry into new markets.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Organogenesis Holdings
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud against Organogenesis Holdings Inc., suggesting that the company and its executives may have engaged in unlawful business practices, prompting investors to reach out for more information.
- Impact of Healthcare Policy: On December 26, 2025, the Centers for Medicare & Medicaid Services announced the withdrawal of final Local Coverage Determinations related to skin substitute grafts, leading to increased competition from over 300 market participants for Organogenesis.
- Stock Price Decline: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a renowned firm in corporate and securities class litigation, having fought for the rights of victims of securities fraud for over 85 years, highlighting its expertise and influence in such cases.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Organogenesis Holdings Inc.
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Organogenesis Holdings Inc. for potential securities fraud and other unlawful business practices, aiming to protect investor rights and possibly lead to a class action lawsuit.
- Impact of Policy Changes: On December 26, 2025, the Centers for Medicare & Medicaid Services withdrew final Local Coverage Determinations related to skin substitute grafts, increasing competitive pressure on Organogenesis from over 300 market participants.
- Stock Price Decline: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in securities, antitrust, and corporate class litigation, having recovered millions of dollars for victims of securities fraud over its 85-year history, showcasing its expertise and influence in the field.
See More
Organogenesis Faces Securities Fraud Investigation, Stock Drops 10.14%
- Securities Fraud Investigation: Pomerantz LLP is investigating Organogenesis Holdings Inc. for potential securities fraud involving the company and its executives, which could undermine investor confidence and lead to stock volatility.
- Increased Market Competition: The withdrawal of final Local Coverage Determinations by the Centers for Medicare & Medicaid Services means Organogenesis will face competition from over 300 market participants, potentially impacting its market share and profitability.
- Stock Price Reaction: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, reflecting market concerns about the company's future outlook.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, may lead to legal liabilities for Organogenesis, further affecting its financial health and investor trust.
See More
Organogenesis Faces Securities Fraud Investigation, Stock Drops 10.14%
- Investigation Launched: Pomerantz LLP is investigating whether Organogenesis Holdings Inc. has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- Policy Change Impact: On December 26, 2025, the Centers for Medicare & Medicaid Services withdrew final Local Coverage Determinations related to skin substitute grafts, meaning Organogenesis will face increased competition from over 300 market participants.
- Stock Price Reaction: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, reflecting market concerns about the company's future prospects.
- Legal Consequences: Pomerantz LLP, a prominent securities class action law firm, may lead to legal liabilities for Organogenesis, further impacting its market performance and investor trust.
See More
Avista Healthcare Partners Promotes Three Key Executives in Investment Team
- Team Promotions: Avista Healthcare Partners has promoted Ryan Moran and Garrett Lustig to Partners, and Elaine Tang to Principal, reflecting the firm's ongoing growth and commitment to talent development in the healthcare investment sector.
- Leadership Enhancement: Managing Partner David Burgstahler noted that these promotions underscore the depth and strength of the firm's leadership team, signaling a strong commitment to pursuing new investment opportunities in the healthcare industry.
- Rich Backgrounds: Ryan Moran, who joined Avista in 2018 after working at Morgan Stanley Capital Partners, currently serves on the boards of several pharmaceutical companies, showcasing his expertise in healthcare investments.
- Strategic Investment: Since its founding in 2005, Avista has invested over $10 billion in more than 50 healthcare businesses globally, focusing on companies with strong management teams and stable cash flows, highlighting its robust growth potential in the healthcare sector.
See More
Organogenesis Reports Record Q4 2025 Earnings Amid Market Uncertainty
- Record Sales: Organogenesis achieved net product revenue of $225.1 million in Q4 2025, representing a 78% year-over-year increase and exceeding expectations by $50 million, primarily driven by an 83% growth in Advanced Wound Care product sales, reflecting strong market demand and effective customer relationships.
- Gross Margin Improvement: The gross profit for Q4 was $175.2 million, or 78% of net product revenue, up from 75% last year, indicating success in cost control and pricing strategies, despite operating expenses rising 39% year-over-year.
- 2026 Outlook: The CFO projected a 25% to 38% decline in total net revenue for 2026, primarily due to clinical confusion stemming from CMS policy changes, with first-quarter revenue expected to drop approximately 50%, although the company remains optimistic about market share growth in the second half of the year.
- Strategic Investments: The CEO highlighted investments in a new manufacturing and R&D center in Rhode Island, along with the launch of Dermagraft and expansion plans for FortiShield and TransCyte, demonstrating the company's commitment to long-term growth and entry into new markets.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Organogenesis Holdings
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud against Organogenesis Holdings Inc., suggesting that the company and its executives may have engaged in unlawful business practices, prompting investors to reach out for more information.
- Impact of Healthcare Policy: On December 26, 2025, the Centers for Medicare & Medicaid Services announced the withdrawal of final Local Coverage Determinations related to skin substitute grafts, leading to increased competition from over 300 market participants for Organogenesis.
- Stock Price Decline: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a renowned firm in corporate and securities class litigation, having fought for the rights of victims of securities fraud for over 85 years, highlighting its expertise and influence in such cases.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Organogenesis Holdings Inc.
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Organogenesis Holdings Inc. for potential securities fraud and other unlawful business practices, aiming to protect investor rights and possibly lead to a class action lawsuit.
- Impact of Policy Changes: On December 26, 2025, the Centers for Medicare & Medicaid Services withdrew final Local Coverage Determinations related to skin substitute grafts, increasing competitive pressure on Organogenesis from over 300 market participants.
- Stock Price Decline: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in securities, antitrust, and corporate class litigation, having recovered millions of dollars for victims of securities fraud over its 85-year history, showcasing its expertise and influence in the field.
See More
Organogenesis Faces Securities Fraud Investigation, Stock Drops 10.14%
- Securities Fraud Investigation: Pomerantz LLP is investigating Organogenesis Holdings Inc. for potential securities fraud involving the company and its executives, which could undermine investor confidence and lead to stock volatility.
- Increased Market Competition: The withdrawal of final Local Coverage Determinations by the Centers for Medicare & Medicaid Services means Organogenesis will face competition from over 300 market participants, potentially impacting its market share and profitability.
- Stock Price Reaction: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, reflecting market concerns about the company's future outlook.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, may lead to legal liabilities for Organogenesis, further affecting its financial health and investor trust.
See More
Organogenesis Faces Securities Fraud Investigation, Stock Drops 10.14%
- Investigation Launched: Pomerantz LLP is investigating whether Organogenesis Holdings Inc. has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- Policy Change Impact: On December 26, 2025, the Centers for Medicare & Medicaid Services withdrew final Local Coverage Determinations related to skin substitute grafts, meaning Organogenesis will face increased competition from over 300 market participants.
- Stock Price Reaction: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, reflecting market concerns about the company's future prospects.
- Legal Consequences: Pomerantz LLP, a prominent securities class action law firm, may lead to legal liabilities for Organogenesis, further impacting its market performance and investor trust.
See More
Avista Healthcare Partners Promotes Three Key Executives in Investment Team
- Team Promotions: Avista Healthcare Partners has promoted Ryan Moran and Garrett Lustig to Partners, and Elaine Tang to Principal, reflecting the firm's ongoing growth and commitment to talent development in the healthcare investment sector.
- Leadership Enhancement: Managing Partner David Burgstahler noted that these promotions underscore the depth and strength of the firm's leadership team, signaling a strong commitment to pursuing new investment opportunities in the healthcare industry.
- Rich Backgrounds: Ryan Moran, who joined Avista in 2018 after working at Morgan Stanley Capital Partners, currently serves on the boards of several pharmaceutical companies, showcasing his expertise in healthcare investments.
- Strategic Investment: Since its founding in 2005, Avista has invested over $10 billion in more than 50 healthcare businesses globally, focusing on companies with strong management teams and stable cash flows, highlighting its robust growth potential in the healthcare sector.
See More
